Targeted Oncology

Journal Title：Targeted Oncology

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.

Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.

Current Opinion articles that place interesting areas in perspective.

Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.

Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.

Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Targeted Oncology 通过提供有关肿瘤学分子靶向药物治疗的文章计划，面向致力于肿瘤学和癌症研究的医生和科学家。期刊包括：

关于分子靶向药物治疗癌症的各个方面的原创研究文章，包括免疫检查点抑制剂和相关方法。

全面的叙述性评论文章和较短的主要文章讨论相关的临床建立以及新兴的药物和途径。

当前观点文章，将有趣的领域放在透视图中。

实践中的治疗文章，这些文章提供了对疾病进行最佳管理的指南，并强调了实际的、临床相关的注意事项和建议。

使用 PRISMA 声明所概述的明确、系统的方法的系统评价。

Adis Drug Review 对肿瘤学中新的和成熟的靶向药物的特性和治疗地位进行了审查。

Targeted Oncology创刊于2006年，由SPRINGER出版商出版，收稿方向涵盖医学 - 肿瘤学全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度>12周，或约稿，影响因子指数4.036，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。